First-line Axitinib plus Pembrolizumab in advanced renal cell carcinoma: retrospective real world data from a multicentre patient cohort

被引：0
|
作者：
Darr, Christopher [1 ,2 ]
Stelmach, Ramona [3 ]
Schlack, Katrin [4 ]
Dinkel, Hendrik [4 ]
Paffenholz, Pia [5 ,6 ]
Ivanyi, Philipp [7 ]
Wiegmann, Jonas [7 ]
Schulz, Anton
Kramer, Mario
Schnabel, Marco [8 ]
Rinderknecht, Emily [8 ]
Handke, Analena [9 ]
Hilser, Thomas
Heidenreich, Axel
Hadaschik, Boris [1 ,2 ,5 ,6 ]
Zschaebitz, Stefanie [3 ]
Gruenwald, Viktor [1 ,2 ,10 ]
机构：
[1] Univ Hosp Essen & German Canc Consortium DKTK, Dept Urol, Essen, Germany
[2] German Canc Consortium DKTK, Essen, Germany
[3] Heidelberg Univ Hosp, Dept Med Oncol, Natl Ctr Tumor Dis, Heidelberg, Germany
[4] Univ Hosp Muenster, Dept Urol, Munster, Germany
[5] Univ Cologne, Fac Med, Dept Urol Urooncol, Robot Assisted & Reconstruct Urol Surg, Cologne, Germany
[6] Univ Hosp Cologne, Cologne, Germany
[7] Dept Hematol Hemostasis Oncol & Stem Cell, Lubeck, Germany
[8] Univ Hosp Regensburg, Dept Urol, Regensburg, Germany
[9] Ruhr Univ Bochum, Marienhospital Herne, Dept Urol, Herne, Germany
[10] Univ Hosp Essen, Dept Oncol, Essen, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2024年 / 47卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
55
引用
收藏
页码：79 / 80
页数：2
相关论文
共 50 条
  • [41] Comparison of axitinib and sunitinib as first-line therapies for metastatic renal cell carcinoma: a real-world multicenter analysis
    Sakae Konishi
    Shingo Hatakeyama
    Toshiaki Tanaka
    Yoshinori Ikehata
    Toshikazu Tanaka
    Naoki Fujita
    Yusuke Ishibashi
    Hayato Yamamoto
    Takahiro Yoneyama
    Yasuhiro Hashimoto
    Kazuaki Yoshikawa
    Toshiaki Kawaguchi
    Naoya Masumori
    Hiroshi Kitamura
    Chikara Ohyama
    Medical Oncology, 2019, 36
  • [42] PHASE 3 STUDY OF PEMBROLIZUMAB plus BELZUTIFAN plus LENVATINIB OR PEMBROLIZUMAB/QUAVONLIMAB plus LENVATINIB VERSUS PEMBROLIZUMAB plus LENVATINIB AS FIRST-LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA
    Choueiri, Toni
    Plimack, Elizabeth
    Powles, Thomas
    Voss, Martin
    Gurney, Howard
    Silverman, Rachel
    Perini, Rodolfo
    Rodriguez-Lopez, Karla
    Rini, Brian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A447 - A447
  • [43] Comparison of axitinib and sunitinib as first-line therapies for metastatic renal cell carcinoma: a real-world multicenter analysis
    Konishi, Sakae
    Hatakeyama, Shingo
    Tanaka, Toshiaki
    Ikehata, Yoshinori
    Tanaka, Toshikazu
    Fujita, Naoki
    Ishibashi, Yusuke
    Yamamoto, Hayato
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Yoshikawa, Kazuaki
    Kawaguchi, Toshiaki
    Masumori, Naoya
    Kitamura, Hiroshi
    Ohyama, Chikara
    MEDICAL ONCOLOGY, 2019, 36 (01)
  • [44] Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma
    Brian I. Rini
    Victor Gruenwald
    Eric Jonasch
    Mayer N. Fishman
    Yoshihiko Tomita
    M. Dror Michaelson
    Jamal Tarazi
    Laura Cisar
    Subramanian Hariharan
    Angel H. Bair
    Brad Rosbrook
    Thomas E. Hutson
    Targeted Oncology, 2017, 12 : 333 - 340
  • [45] Re: Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
    Teh, Jiasian
    Narasimhan, Vignesh
    Schultz, Stephen
    Sathianathen, Niranjan
    Murphy, Declan G.
    EUROPEAN UROLOGY, 2019, 76 (01) : 126 - 127
  • [46] Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma
    Rini, Brian I.
    Gruenwald, Victor
    Jonasch, Eric
    Fishman, Mayer N.
    Tomita, Yoshihiko
    Michaelson, M. Dror
    Tarazi, Jamal
    Cisar, Laura
    Hariharan, Subramanian
    Bair, Angel H.
    Rosbrook, Brad
    Hutson, Thomas E.
    TARGETED ONCOLOGY, 2017, 12 (03) : 333 - 340
  • [47] Pembrolizumab plus axitinib: another step ahead in advanced renal cell carcinoma Comment
    Procopio, Giuseppe
    Nichetti, Federico
    Verzoni, Elena
    LANCET ONCOLOGY, 2020, 21 (12): : 1538 - 1539
  • [48] Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma
    Spisarova, Martina
    Melichar, Bohuslav
    Vitaskova, Denisa
    Studentova, Hana
    FUTURE ONCOLOGY, 2021, 17 (03) : 241 - 254
  • [49] Trial in progress: phase 1b dose-finding study of axitinib plus pembrolizumab for first-line treatment of advanced renal cell carcinoma (RCC)
    Choueiri, T. K.
    Plimack, E. R.
    Gupta, S.
    Cho, D.
    Hutson, T. E.
    Puzanov, I.
    George, S.
    Olencki, T.
    Vaishampayan, U.
    Chakrabarti, D.
    Pithavala, Y. K.
    Williams, J. A.
    Rosbrook, B.
    Tarazi, J. C.
    Atkins, M. B.
    BJU INTERNATIONAL, 2014, 114 : 4 - 5
  • [50] A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma
    Lu, Peiyao
    Liang, Weiting
    Li, Jiahao
    Hong, Yanming
    Chen, Zhuojia
    Liu, Tao
    Dong, Pei
    Huang, Hongbing
    Zhang, Tiantian
    Jiang, Jie
    FRONTIERS IN PHARMACOLOGY, 2020, 11
12345